论文部分内容阅读
约15%～25%的乳腺癌表现为HER-2的过表达。HER-2阳性乳腺癌患者其复发及死亡风险较高。曲妥珠单克隆抗体(H)为一种重组DNA衍生的人源化单克隆抗体,可选择性作用于HER-2蛋白的胞外域。美国北部癌症治疗中心协作组(NCCTG)N9831试验和B-31试验表明:曲妥珠单克隆抗体可提高HER-2阳
About 15% to 25% of breast cancers show HER-2 overexpression. Patients with HER-2 positive breast cancer have a higher risk of recurrence and death. Trastuzumab (H) is a recombinant DNA-derived humanized monoclonal antibody that selectively acts on the extracellular domain of the HER-2 protein. North American Cancer Treatment Center Cooperative Group (NCCTG) N9831 trial and B-31 trial showed that trastuzumab monoclonal antibody raised HER-2 positive